Quest Diagnostics rumored to have hired Goldman following USD 95/share approach
Quest Diagnostics (NYSE: DGX), the medical testing business based in Madison, New Jersey, is rumored to have received a takeover approach priced at USD 95 per share, a newswire report said. Shares in New York-listed Quest leapt to USD 89 from around USD 74 after the rumor was posted on Twitter by OptionsHawk.com founder Joe Kunkle, Bloomberg reported late on 22 May. OptionsHawk.com offers market research and analysis to subscribers, the company’s website states.
Quest was said to have appointed Goldman Sachs to consider a potential sale of the business after the approach was made, the item reported, adding that several prospective buyers were believed to be showing an interest.
Kunkle subsequently deleted his tweet, stating that it had not been taken in the right context; he explained that the message was just internet-based speculation from unidentified sources which he was passing along.
A Quest spokesperson declined to comment, the report said.